NASAA has proposed replacing the single Franchise Disclosure Document State Cover Page with three new pages that may provide additional guidance, information and warnings to prospective ...

President Donald Trump on Friday dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular but costly GLP-1 treatments such as Novo Nordisk's Wegovy and Eli ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded coverage of costly anti-obesity drugs to more than 7 million Americans on ...

The Biden administration’s proposal estimates that the coverage will cost the federal government nearly $40 billion in the next decade, with Medicare making up $25 billion of the total cost. Other ...

President Donald Trump dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular GLP-1 treatments such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

President Donald Trump dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular GLP-1 treatments such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

President Donald Trump dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular GLP-1 treatments such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.